Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dirlotapide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP known ✓ | P55157 | 19/20 | 1.00 |
| ▸ | KLRK1 | P26718 | 1/20 | 0.50 |
| ▸ | MICA | Q29983 | 1/20 | 0.50 |
| ▸ | RAET1L | Q5VY80 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dirlotapide SCHEMBL691507 | 1.00 | MTTP (1.00) | MTTPKLRK1MICARAET1L | |
| SCHEMBL13945890 | 0.93 | MTTP (0.86) | MTTP | |
| SCHEMBL4740096 | 0.92 | MTTP (0.85) | MTTP | |
| SCHEMBL6313410 | 0.91 | MTTP (0.84) | MTTP | |
| SCHEMBL6312907 | 0.90 | MTTP (0.82) | MTTP | |
| SCHEMBL13945871 | 0.90 | MTTP (0.82) | MTTP | |
| SCHEMBL5090234 | 0.86 | MTTP (0.76) | MTTP | |
| SCHEMBL1620341 | 0.86 | MTTP (1.00) | MTTPKLRK1MICARAET1L | |
| SCHEMBL690744 | 0.85 | MTTP (0.81) | MTTP | |
| SCHEMBL4186328 | 0.85 | MTTP (0.81) | MTTP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023101441-A1 | USE OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR IN TREATMENT OF FIBROSIS DISEASE | 에스케이케미칼 주식회사 | 2023-06-08 | — | — | WO | claimed |
| WO-2022207950-A1 | TREATMENT FOR OBESITY | FUNDACION UNIVERSITARIA SAN ANTONIO (UCAM) (ES) | 2022-10-06 | — | — | WO | claimed |
| EP-3366306-A2 | USE OF SOME PEPTIDES IN DIAGNOSIS AND TREATMENT OF DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-08-29 | — | — | EP | claimed |
| EP-3351262-A1 | CURAGLUTIDE FOR IN TREATMENT OF PREDIABETES, DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-07-25 | — | — | EP | claimed |
| EP-3119757-B1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC AND RELATED DISORDERS | PFIZER (US) | 2018-05-16 | — | — | EP | claimed |
| US-20180021341-A1 | ACC INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | GILEAD APOLLO, LLC | 2018-01-25 | — | — | US | claimed |
| EP-3242722-A1 | ACC INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | Gilead Apollo, LLC (US) | 2017-11-15 | — | — | EP | claimed |
| CN-107106873-A | ACC inhibitor combined therapies for treating non-alcoholic fatty liver disease | 吉利德阿波罗公司 | 2017-08-29 | — | — | CN | claimed |
| EP-2834238-B1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER (US) | 2017-02-01 | — | — | EP | claimed |
| EP-3119757-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC AND RELATED DISORDERS | Pfizer Inc. (US) | 2017-01-25 | — | — | EP | claimed |
| US-7348355-B2 | Treating obesity with the Microsomal triglyceride transfer protein inhibitor (S) N-{2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl}-1-methyl-5-[4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamido]-1H-indole-2-carboxamide and another lipid lowering agent such as a statin or fibrate | PFIZER INC. (US) | 2008-03-25 | — | — | US | claimed |
| EP-1890767-A2 | COMBINATION OF A CANNABINOID-1- RECEPTOR-ANTAGONIST AND A MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR FOR TREATING OBESITY OR MAINATAINING WEIGHT LOSS | Pfizer Products Inc. (US) | 2008-02-27 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2006129193-A2 | COMBINATION OF A CANNABINOID-1- RECEPTOR-ANTAGONIST AND A MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR FOR TREATING OBESITY OR MAINATAINING WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2006-12-07 | — | — | WO | claimed |
| US-20060270655-A1 | Combination therapy for treating obesity or maintaining weight loss | SWICK ANDREW G | 2006-11-30 | — | — | US | claimed |
| US-20060194772-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2006-08-31 | — | — | US | claimed |
| US-20040087625-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2004-05-06 | — | — | US | claimed |
| US-6720351-B2 | 1H-INDOLE-2-CARBOXYLIC ACID (2-(BENZYL(METHYL)AMINO) -2-OXO-1-PHENYLETHYL)AMIDES; TRIAMIDE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) AND APOLIPOPROTEIN B (APO B) INHIBITORS; OBESITY; ANTILIPEMIC AGENTS | PFIZER INC. | 2004-04-13 | — | — | US | claimed |
| US-20030187053-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC. | 2003-10-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194772-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | MTTP 3/4885KLRK1 4007/4885MICA 1998/4885 |
| US-20040087625-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | MTTP 3/4885KLRK1 3958/4885MICA 1470/4885 |
| US-20030187053-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | MTTP 3/4885KLRK1 3958/4885MICA 1470/4885 |
| US-20180021341-A1 | ACC INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | ACACA, ACACB, ACAT1 | MTTP 197/4885KLRK1 4697/4885MICA 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.